You are here
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding18 June 2020
The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.
This document provides background to the development of the new classification, explains the data elements and collection protocols, reporting requirements, and how the data is grouped.
This document provides an overview of the content of the ATTC Version 1.0 including the scope, structure and relevant activities.
Hospital Teaching, Training and Research Activities National Best Endeavours Data Set 2018-19 Technical Specifications for reporting5 July 2018
This document outlines the reporting requirements for the provision of data against the HTTRA NBEDS 2018-19 by state and territory health departments, including:
This guide is intended to provide assistance when assigning care types, especially for those patients that may potentially have care that applies to more than one care type.